Shares of Bellerophon Therapeutics Inc. BLPH, +5.06% gained 38% in premarket trading on Tuesday after its experimental therapy to treat certain forms of pulmonary hypertension reported positive clinical data. The Warren, N.J.-based company said that the Inopulse, a device that dispenses nitric oxide, showed an improvement in moderate to vigorous physical activity for patients taking the drug in an ongoing Phase 2/3 trial. A late-stage trial is expected to launch in the first quarter of next year. Bellerophon’s stock is down 47% year-to-date. The S&P 500 SPX, +0.11% is up 27%.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.